Back to search results

GLUCID Study: Alcohol Reduction and Probiotics for Cognition in Older Adults

This study, called GLUCID, is looking at how two interventions might affect thinking skills (cognition) and brain sugar use (metabolism) in older adults (ages 65-84) who drink a lot of alcohol. You would receive either a probiotic called Visbiome or a placebo (an inactive substance that looks like the probiotic) for 30 days. You would also have one counseling session to help reduce alcohol use. Researchers want to see if these interventions improve your thinking abilities and how your brain uses energy. The study aims to enroll 20 participants, but its current status is unclear.

Study design
This is an interventional study exploring two approaches: a behavioral intervention (motivational interviewing) and a blinded probiotic or placebo. It plans to enroll 20 participants.
What's involved
You would receive a daily dietary supplement (Visbiome or placebo) for 30 days. You would also have one video call counseling session lasting up to 30 minutes.
Compensation
Not stated in the trial record.
Follow-up
Your cognition and brain metabolism will be measured at the beginning of the study and again after 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07415707

The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers

Recruiting
NAAges 65–84InterventionalBasic science
University of Miami
~20 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:VisbiomeMotivational InterviewingPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Total Cognition Composite score
Measured over Baseline, 30 days
+1 more outcome measured

Conditions

Aging
Alcohol Drinking

Explore related trials

AgingAlcohol Consumption

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Teddy Salan, PhD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Teddy Salan, PhD
[email protected]
305-243-9228
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Between 65 and 84 years of age
English speaking
Able to provide valid informed consent, understand requirement and risk/benefits of the study and comply with study protocol
Heavy drinker defined as \>14 alcoholic drinks/week for men and \>7 drinks/week for women
Interested in reducing their alcohol consumption

Exclusion

BMI ≥ 35
Fasting Glucose \> 125 mg/dL
Current or previously diagnosed with Type 1 or 2 Diabetes
Requires the use of insulin and/or other glucose lowering agents
Unable to fast for 12 hours
Past serious alcohol withdrawal symptoms
MRI Contraindications (e.g., certain devices and implants, claustrophobic)
Diagnosed with a neurodegenerative disease (e.g., Alzheimer's Disease)
Diagnosed with a psychotic disorder
Current substance dependence diagnosis (except for mild or moderate alcohol)
Consumption of over 300 drinks in the past 30 days
Current probiotic use or recent probiotic use within the past 30 days
Current antibiotic use or recent antibiotic use within the past 30 days
In active cancer treatment and/or have advanced cancer
Taking daily steroids and/or immunosuppressants
Lifetime organ or bone marrow transplant; primary immunodeficiency (e.g., DiGeorge syndrome or Wiskott-Aldrich syndrome) or transplant recipient or prescribed immunosuppressant medications
PI's discretion

What this trial measures

  • Change in Total Cognition Composite scoreBaseline, 30 days

    Cognitive performance will be assessed using the NIH Toolbox Cognition Battery v3 to measure the Total Cognition Composite score at two time-points and examined for change within subjects.

  • Change in Brain MetabolismBaseline, 30 days

    Brain metabolism will be assessed using magnetic resonance spectroscopy (MRS) to quantify glucose uptake.